Health Care

Immix Biopharma insiders, led by senior exec Chang Nancy T, buying RSUs signals confidence in its oncology pipeline and potential valuation rebound.

Insider buying surges at Neuronetics, boosting confidence in its neuro‑health strategy; discover what this means for investors and potential valuation gains.

BrainStorm insiders buy 1.8 M RSUs at no cost, boosting CEO holdings by 10 %—a bullish sign ahead of Phase 3b trials and possible funding boosts.

Insider buying spree by Zhu Theodore boosts confidence in Axe Compute’s AI‑powered oncology platform and GPU growth, signaling a promising long‑term play for investors.

Insider selling at Stryker Corp. shows disciplined, plan‑based trades – not a crisis – offering insight into executive confidence and market impact.

Juniper Investment’s recent buy of Orthofix shares signals “buy‑the‑dip” optimism amid a steep decline, weak earnings and governance scrutiny—watch the stock’s rebound chances.

Insider sale of 567 shares by Edwards Lifesciences SVP Andrew M. Dahl – what this signals for investor confidence and future stock performance.

Insider confidence shines as Kristina Burow and other execs buy 80,000 options in Neumora Therapeutics, hinting at upside amid market volatility and a low 52‑week price.

Insider buying spikes at Charlotte’s Web Holdings as a BAT‑owned subsidiary acquires 15% stake, boosting debt‑to‑equity and signaling investor confidence in the company’s cannabis‑derived wellness strategy.

Exelixis insider activity: David Johnson’s new 19,133‑option grant shows bullish confidence amid market caution—what it means for investors and the company’s future.